Evidence map›Paper›PMID 35445023›Full record

ReviewFrontiers in cell and developmental biology2022

N

Bo Wei, Meiyu Zeng, Jing Yang, Shuainan Li, Jiantao Zhang, Nan Ding, Zhisheng Jiang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. NMolecular medicine reports · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bo WeiResearch Lab of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Meiyu ZengResearch Lab of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Jing YangResearch Lab of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Shuainan LiResearch Lab of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Jiantao ZhangInstitution of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, China.
Nan DingInstitution of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, China.
Zhisheng JiangKey Laboratory for Arteriosclerology of Hunan Province, Human International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Institute of Cardiovascular Disease, Hengyang Medical College, University of South China, Hengyang, China.
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell transplantation (SCT) holds great promise for overcoming diseases by regenerating damaged cells, tissues and organs. The potential for self-renewal and differentiation is the key to SCT. RNA methylation, a dynamic and reversible epigenetic modification, is able to regulate the ability of stem cells to differentiate and regenerate.

Indexed as

differentiationN6-methyladenosineproliferationRNA modificationstem cell

Identifiers

PMID35445023
PMCPMC9013802
OpenAlexW4226170826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.